Xeris Biopharma Holdings, Inc.
As of Oct 22, 2026, Xeris Biopharma Holdings is in Stage 2, the uptrend phase, now in week 14 (since Jul 20, 2026). It closed at $10.86, 2.4% below its 52-week high and above its 200-day average, which is rising.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is XERS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
XERS among Drug Manufacturers - Specialty & Generic20th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …20 | XERS | Stage 2 · wk 14 | 70 | +25.4% |
Xeris Biopharma Holdings: quick answers
What stage is Xeris Biopharma Holdings in?
As of Oct 22, 2026, Xeris Biopharma Holdings (XERS) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 20, 2026 and is in week 14. What the four stages mean
Is Xeris Biopharma Holdings in an uptrend?
Yes. Xeris Biopharma Holdings is in a Stage 2 uptrend. It trades 46.4% above its 200-day average, which is rising.
How far is Xeris Biopharma Holdings from its 52-week high?
Xeris Biopharma Holdings closed at $10.86 on Oct 22, 2026, 2.4% below its 52-week high of $11.13. Its 52-week low is $5.29.
How has Xeris Biopharma Holdings performed over the past year?
As of Oct 22, 2026, Xeris Biopharma Holdings is up 19.6% over the past year and up 47.8% so far in 2026.
Which sector and industry is Xeris Biopharma Holdings in?
Xeris Biopharma Holdings is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.